Inhibition of liver ApoC3 by GalNAc-conjugated siRNA RBD5044: first-in-human trial to evaluate the safety, pharmacokinetics (PK), and pharmacodynamic (PD) effects on atherogenic lipid profiles in heal
Event: ESC Congress 2025
Topic: Lipid-Lowering Agents
Session: Novel insights into lipid-lowering pharmacotherapy
siRNA-mediated inhibition of PCSK9 by RBD7022: a first-in-human trial to evaluate safety, pharmacokinetics (PK) and pharmacodynamic (PD) effects alone and when added to statin treatment.
Event: ESC Congress 2025
Topic: Lipid-Lowering Agents
Session: Dyslipidaemias: current strategies and innovations
First-in-human study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of RBD4059, a GalNAc-siRNA drug targeting coagulation factor XI (FXI), in healthy subjects
Event: ESC Congress 2024
Topic: Anticoagulants
Session: Biotherapies in cardiovascular disease: from bench to bedside
